HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS
申请人:Ramsden Nigel
公开号:US20120252779A1
公开(公告)日:2012-10-04
The invention relates to compounds of formula (I)
wherein X
1
to X
5
, Y, Z
1
to Z
3
, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS
申请人:Bell Kathryn
公开号:US20130190292A1
公开(公告)日:2013-07-25
The present invention relates to compounds of formula (I)
wherein X
1
to X
5
, Y, Z
1
to Z
3
, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
申请人:Bell Kathryn
公开号:US09040545B2
公开(公告)日:2015-05-26
The present invention relates to compounds of formula (I)
wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
申请人:Ramsden Nigel
公开号:US09242987B2
公开(公告)日:2016-01-26
The invention relates to compounds of formula (I)
wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.